The BioPharm Brief: Long-Term Clinical Durability Advances Rare Disease Treatment Strategies

Feb 23, 09:34 PM
Headliner
Share
Subscribe

Today’s podcast highlights how sustained clinical efficacy data in alpha-thalassemia and ulcerative colitis highlight durability as a defining benchmark in modern biologic drug development.

Share
Subscribe
Next
The BioPharm Brief: Trial Recruitment Challenges and Reshaping Workforce Strategies
Top episodes
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
by The BioPharm Brief
The BioPharm Brief: Cancer, Personalized
by The BioPharm Brief
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
by The BioPharm Brief